Cause
The cause of
Alzheimer's disease is not clear, and it is likely
there are several causes of this condition. Alzheimer's disease causes changes
or deterioration in certain areas of the brain that control thinking,
communication, and behavior. Some of the deterioration may be related to a loss
of chemical messengers in the brain (neurotransmitters)—acetylcholine, in particular—that
allow nerve cells in the brain to communicate properly.
It is not
clear why these changes in the brain occur, but they are a major focus of
Alzheimer's research. Although most people who have Alzheimer's disease do not
have a
family history of the condition, you are at increased
risk for the condition if a member of your family has it.
Some
theories have suggested that metals, such as zinc or aluminum, play a role in
Alzheimer's disease. But research has not found much evidence to support these
theories. Experts agree that there is no reason to leave zinc out of your diet
or to avoid items that contain aluminum, such as cooking utensils or soda pop
cans.
Beers MH, et al., eds. (2004). Merck Manual of Health and Aging. Whitehouse Station, NJ: Merck Research
Laboratories.
Alzheimer's Association (2007). Symptoms of Alzheimer’s. Available online: http://www.alz.org/alzheimers_disease_symptoms_of_alzheimers.asp.
Espeland MA, et al. (2004). Conjugated equine
estrogens and global cognitive function in postmenopausal women: Women's Health
Initiative memory study. JAMA, 291(24):
2959–2968.
Shumaker SA, et al. (2004). Conjugated equine
estrogens and incidence of probable dementia and mild cognitive impairment in
postmenopausal women: Women's Health Initiative memory study. JAMA, 291(24): 2947–2958.
Wang L, et al. (2006). Performance-based physical function and future dementia in older people. Archives of Internal Medicine, 166(10): 1115–1120.
Wilson RS, et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287(6): 742–748.
Wilson RS, et al. (2007). Relation of cognitive
activity to risk of developing Alzheimer disease. Neurology, 69(20): 1911–1920.
Barberger-Gateau P, et al. (2007). Dietary patterns
and risk of dementia: The three-city cohort study. Neurology, 69(20): 1921–1930.
Sofi F, et al. (2008). Adherence to Mediterranean diet
and health status: Meta-analysis. BMJ. Published online
September 11, 2008 (doi:10.1136/bmj.a1344).
Tariot PN, et al. (2004). Memantine treatment in
patients with moderate to severe Alzheimer's disease already receiving
donepezil. JAMA, 291(3): 317–324.
Sink KM, et al. (2005). Pharmacological treatment of
neuropsychiatric symptoms of dementia: A review of the evidence.
JAMA, 293(5): 596–608.
Trinh NH, et al. (2003). Efficacy of cholinesterase
inhibitors in the treatment of neuropsychiatric symptoms and functional
impairment in Alzheimer disease: A meta-analysis. JAMA,
289(2): 210–216.
Raina P, et al. (2008). Effectiveness of
cholinesterase inhibitors and memantine for treating dementia: Evidence review
for a clinical practice guideline. Annals of Internal Medicine, 148(5): 379–397.
Howard RJ, et al. (2007). Donepezil for the treatment
of agitation in Alzheimer's disease. New England Journal of Medicine, 357(14): 1382–1392.
Warner J, et al. (2008). Dementia, search date
February 2006. Online version of BMJ Clinical Evidence.
Also available online: http://clinicalevidence.com.
Ballard CG, et al. (2002). Aromatherapy as a safe and
effective treatment for the management of agitation in severe dementia: The
results of a double-blind placebo-controlled trial with Melissa.
Journal of Clinical Psychiatry, 63(7):
553–558.